Stock comparison
Moderna, Inc. is 2.1x more valuable than EXELIXIS, INC. by market capitalization ($30.38 B vs $14.35 B). Compare market value, revenue, profit, margins, filings, and source pages in one place.
Quick answer
MRNA is larger
Moderna, Inc. is 2.1x more valuable than EXELIXIS, INC. by market capitalization ($30.38 B vs $14.35 B).
Market value leader
MRNA
Moderna, Inc. is 2.1x more valuable than EXELIXIS, INC. by market capitalization ($30.38 B vs $14.35 B).
Revenue leader
EXEL
EXEL: $2.32B vs MRNA: $1.94B.
Profit leader
EXEL
EXEL: $782.60M vs MRNA: -$2.82B.
Margin leader
EXEL
EXEL: 33.7% vs MRNA: -145.2% net margin.
| Metric | EXEL | MRNA |
|---|---|---|
| Market cap | $14.35 B | $30.38 B |
| US-listed rank | #763 | #461 |
| Revenue (latest FY) | $2.32B | $1.94B |
| Net income (latest FY) | $782.60M | -$2.82B |
| Net margin | 33.7% | -145.2% |
| P/E (trailing FY) | 18.3x | - |
| SEC filings | 2,488 | 1,447 |
Jump from this comparison into the underlying pages for market value, annual fundamentals, and company filing history.
Market cap uses refreshed market data. Revenue, net income, margins, and trailing fiscal-year P/E use annual company facts from filings. If a metric is missing, the source data did not have a clean recent annual value for that company.
Moderna, Inc. is 2.1x more valuable than EXELIXIS, INC. by market capitalization ($30.38 B vs $14.35 B).
In their latest fiscal years, EXELIXIS, INC. reported $2.32B in revenue while Moderna, Inc. reported $1.94B.
Full pages: EXELIXIS, INC. and Moderna, Inc., or browse the full rankings.